Eficacia del tratamiento con sulfato de magnesio en pacientes con preeclampsia, como prevención de la eclampsia, en embarazadas atendidas en el Hospital Dr: Rafael Rodríguez Zambrano, de la ciudad de Manta. De septiembre del 2012 a febrero del 2013
Fecha
2013
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Carrera de Obstetricia
Resumen
La Preeclampsia es un trastorno multisistémico del embarazo y puerperio, que
complica aproximadamente al 6 a 8% de todos los embarazos en países
desarrollados de acuerdo a la OMS. No existe una prueba específica para su
diagnóstico, y este se basa en la valoración clínica de: hipertensión arterial > 140
mmHg de sistólica o > 90 mmHg de diastólica tomada en posición sentada,
proteinuria (>0.3 gr. en 24 horas). La preeclampsia se clasifica en moderada o
grave, en base a la severidad de la hipertensión y proteinuria, edema, y la
presencia de síntomas y signos que manifiesten compromiso de otros órganos. En
la preeclampsia severa, la presión arterial sobrepasa los 160/110 mmHg, El
estudio es de tipo descriptivo con diseño no experimental, longitudinal,
prospectivo. Los resultados obtenidos expresaron que de acuerdo a la edad de la
paciente, el mayor porcentaje de preeclampsia se presentó en mujeres de 35 a 39
años de edad 25%, seguido de 15 a 19 años y de 25 a 29 años con 21%
simultáneamente, de 20 a 24 años con 18%, de 30 a 34 años con el 9% mientras
que el menor porcentaje lo presentó pacientes de 40 a 44 años con 6%. Se
demuestro que el tratamiento de elección en pacientes con preeclampsia como
profilaxis de eclampsia, en 33 pacientes es el sulfato de magnesio equivalente al
100%. El análisis muestra que de las 33 pacientes con preeclampsia que
recibieron el Tratamiento de sulfato de magnesio, siendo el 100%, ninguna hizo
Eclampsia. Estos resultados nos permitirán evaluar y analizar, un plan o
protocolo que pueda ser recomendado al Ministerio de Salud Publica para
disminuir la morbi - mortalidad en este grupo de pacientes.
Preeclampsia is a multisystem disorder of pregnancy and postpartum, Complicating approximately 6 to 8% of all pregnancies in countries developed according to WHO. There is no specific test for diagnosis, and this is based on the clinical assessment of: high blood pressure> 140 mmHg systolic or> 90 mmHg diastolic taken in a sitting position, proteinuria (> 0.3 g. Within 24 hours). Preeclampsia is classified as moderate or severe, based on the severity of hypertension and proteinuria, edema, and the presence of symptoms and signs that express involvement of other organs. In severe preeclampsia, blood pressure exceeds 160/110 mmHg, the study is descriptive, non-experimental, longitudinal, prospective study. The results expressed conclude that according to the age of the patient, the highest percentage of pre-eclampsia occurred in women 35 to 39 years old 25%, followed by 15 to 19 years and 25 to 29 years with 21% simultaneously , 20 to 24 years with 18%, while the lowest percentage is present patients 40 to 44 years with 6%. Demonstrated that treatment of choice for patients with preeclampsia and eclampsia prophylaxis in 33 patients magnesium sulfate is equivalent to 100%. The analysis shows that the 33 patients with preeclampsia who received magnesium sulfate treatment, with 100%, neither did Eclampsia. . These results allow us to evaluate and analyze, plan or protocol that can be recommended to the Ministry of Public Health to reduce morbidity - mortality in this group of patients.
Preeclampsia is a multisystem disorder of pregnancy and postpartum, Complicating approximately 6 to 8% of all pregnancies in countries developed according to WHO. There is no specific test for diagnosis, and this is based on the clinical assessment of: high blood pressure> 140 mmHg systolic or> 90 mmHg diastolic taken in a sitting position, proteinuria (> 0.3 g. Within 24 hours). Preeclampsia is classified as moderate or severe, based on the severity of hypertension and proteinuria, edema, and the presence of symptoms and signs that express involvement of other organs. In severe preeclampsia, blood pressure exceeds 160/110 mmHg, the study is descriptive, non-experimental, longitudinal, prospective study. The results expressed conclude that according to the age of the patient, the highest percentage of pre-eclampsia occurred in women 35 to 39 years old 25%, followed by 15 to 19 years and 25 to 29 years with 21% simultaneously , 20 to 24 years with 18%, while the lowest percentage is present patients 40 to 44 years with 6%. Demonstrated that treatment of choice for patients with preeclampsia and eclampsia prophylaxis in 33 patients magnesium sulfate is equivalent to 100%. The analysis shows that the 33 patients with preeclampsia who received magnesium sulfate treatment, with 100%, neither did Eclampsia. . These results allow us to evaluate and analyze, plan or protocol that can be recommended to the Ministry of Public Health to reduce morbidity - mortality in this group of patients.
Descripción
PDF
Palabras clave
Preeclampsia, Embarazo, Eclampsia, Sulfato de magnesio, Complicaciones, Hospital Dr: Rafael Rodríguez Zambrano, Canton Manta, Ecuador